Childhood cancers trials in Poland

In Poland 49 Also abroad 2459

49 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
Where
Bialystok, Cracow, Gdansk, Gliwice, Lodz, Poznan, Warsaw, Wroclaw
Age
15 years and over
People
800 worldwide
Run by
AstraZeneca
See details and how to joinNCT06079671 · EU 2023-504374-38-00
Phase 2Taking people
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Where
Gdansk, Wroclaw
Age
1 year to 18 years
People
50 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07354074
Phase 4Taking people
Asciminib Roll-over Study
Where
Katowice, Krakow, Warsaw, Wroclaw
Age
7 years to 100 years
People
347 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00
Phase 3Taking people
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
Where
Gda?sk, Koszalin, Warsaw
People
200 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05862285 · EU 2023-504263-16-00
Phase 1/2Taking people
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Where
Wroclaw
Age
6 months to 30 years
People
65 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05533775
Phase 1/2Taking people
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination with Chemoimmunotherapy in Pediatric and Young Adult Participants with Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Where
Wroclaw
Age
Up to 17 years
People
37 worldwide
Run by
F. Hoffmann-La Roche AG
See details and how to join2023-504264-41-00 · EU 2023-504264-41-00
Phase 2/3Taking people
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Where
Bytom, Gdansk, Gliwice, Lodz, Lublin, Warsaw
People
1,541 worldwide
Run by
Celgene
See details and how to joinNCT03435796 · EU 2023-504201-36-00
Phase 1Not yet taking people in Poland
Phase I study of CDK8 inhibitor RVU120 in combination with everolimus in children with recurrent or progressive Group 3 or 4 medulloblastoma; MEDWAY
Where
Warsaw
Age
Up to 17 years
People
48
Run by
Instytut Pomnik Centrum Zdrowia Dziecka
See details and how to join2025-524031-39-00 · EU 2025-524031-39-00
No phaseTaking people
Master Framework For Relapse or Refractory Acute Myeloid Leukemia
Where
Gdansk
Age
6 years and over
People
4,000 worldwide
Run by
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
See details and how to joinNCT06459024
Phase 3Taking people
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
Where
Wroclaw
Age
1 year to 64 years
People
750 worldwide
Run by
Charite University, Berlin, Germany
See details and how to joinNCT07476729 · EU 2023-509392-17-00
Phase 3Taking people
Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse
Where
Warsaw
Age
4 years and over
People
530 worldwide
Run by
Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT07871864
Phase 2/3Taking people
Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants
Where
Lodz, Warsaw
Age
4 weeks to 16 weeks
People
60
Run by
Katarzyna Kotulska
See details and how to joinNCT04987463 · EU 2024-513068-25-00
Phase 3Taking people
Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis Complex
Where
Lodz, Warsaw
Age
3 months to 50 years
People
200
Run by
Katarzyna Kotulska
See details and how to joinNCT05534672 · EU 2024-515937-13-00
Phase 3Taking people
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Where
Bydgoszcz, Lublin, Olsztyn, Opole, Walbrzych, Wroclaw
Age
12 years and over
People
468 worldwide
Run by
Syndax Pharmaceuticals
See details and how to joinNCT07211958 · EU 2025-522279-27-00
Phase 2/3Taking people
Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL
Where
Poznan
Age
3 months to 25 years
People
1,000 worldwide
Run by
Bambino Gesù Hospital and Research Institute
See details and how to joinNCT07297914 · EU 2025-522052-13-00
Phase 3Taking people
International Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma
Where
Warsaw
Age
Up to 64 years
People
1,351 worldwide
Run by
GPOH gGmbH
See details and how to join2022-501180-40-00 · EU 2022-501180-40-00
Phase 3Taking people
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
Where
Bialystok, Bydgoszcz, Chorzów, Cracow, Gdansk, Katowice, Kielce, Lodz, Lublin, Olsztyn, Poznan, Rzeszów, Szczecin, Warsaw, Wroclaw, Zabrze
Age
1 day to 1 year
People
160 worldwide
Run by
Princess Maxima Center for Pediatric Oncology
See details and how to joinNCT05327894 · EU 2022-502503-30-00
Phase 1Not yet taking people in Poland
Study of CDK8 Inhibitor RVU120 in Combination With Everolimus in Children With Recurrent or Progressive Group 3 or 4 Medulloblastoma
Where
Warsaw
Age
3 years to 18 years
People
48
Run by
Bożenna Dembowska Bagińska
See details and how to joinNCT07865130
Phase 2Taking people
To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly)
Where
Warsaw, Wroclaw
Age
2 years to 21 years
People
24
Run by
Anna Raciborska
See details and how to joinNCT05968768
Phase 2Taking people
Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma
Where
Warsaw
Age
5 months to 30 years
People
40
Run by
Anna Raciborska
See details and how to joinNCT07787429
Phase 2/3Taking people
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Where
Gdansk, Gliwice, Konin, Siedlce, Warsaw
Age
18 years and over
People
740 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT06697301 · EU 2024-512659-19-00
Phase 2Taking people
Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)
Where
Bialystok, Bydgoszcz, Lodz, Lublin, Olsztyn, Poznan, Szczecin, Warsaw
Age
0 months to 18 years
People
95 worldwide
Run by
Helsinn Healthcare SA
See details and how to joinNCT06904235
Phase 2Taking people
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
Where
Bydgoszcz, Wroclaw
Age
1 year to 17 years
People
100 worldwide
Run by
Pfizer
See details and how to joinNCT05748171 · EU 2023-509810-13-00
Phase 3Taking people
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Where
Cracow, Gdansk, Gliwice, Poznan, Warsaw, Warszawa
Age
12 years to 100 years
People
240 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06784752 · EU 2024-518325-15-00
Phase 2/3Taking people
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Where
Bydgoszcz, Krakow, Lublin, Poznan, Wroclaw
Age
1 month to 18 years
People
1,800 worldwide
Run by
St. Anna Kinderkrebsforschung
See details and how to joinNCT01949129 · EU 2024-512657-24-00